Literature DB >> 19252307

Involvement of the CYP1A subfamily in stereoselective metabolism of carvedilol in beta-naphthoflavone-treated Caco-2 cells.

Kazuya Ishida1, Masato Taguchi, Teruaki Akao, Yukiya Hashimoto.   

Abstract

We have previously reported that the metabolism of S-carvedilol in beta-naphthoflavone (beta-NF)-treated Caco-2 cells is faster than that of R-carvedilol. The aim of the present study was to identify the enzyme responsible for the stereoselective metabolism of carvedilol in the cells. The expression of cytochrome P450 (CYP) 1A1 and CYP1A2 mRNA, but not CYP2D6, CYP3A4, and CYP2C9 mRNA, was increased in beta-NF-treated Caco-2 cells, as compared with non-treated cells. Furafylline, an inhibitor of the CYP1A subfamily, decreased the metabolism of S-carvedilol in Caco-2 cells cultured on plastic dishes. In addition, the glucuronidation of carvedilol was not significant in microsomes of beta-NF-treated Caco-2 cells. On the other hand, the oxidation of S-carvedilol in microsomes of beta-NF-treated Caco-2 cells was faster than that of R-carvedilol, and furafylline decreased the oxidative activity of S-carvedilol. These findings suggested that the CYP1A subfamily was responsible for the stereoselective metabolism of carvedilol in beta-NF-treated Caco-2 cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19252307     DOI: 10.1248/bpb.32.513

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  2 in total

1.  Effect of chronic hypoxic hypoxia on oxidation and glucuronidation of carvedilol in rats.

Authors:  Shizuka Yamaura; Miki Fukao; Kazuya Ishida; Masato Taguchi; Yukiya Hashimoto
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-06-06       Impact factor: 2.441

2.  CYP1A1 and CYP1B1-mediated biotransformation of the antitrypanosomal methamidoxime prodrug DB844 forms novel metabolites through intramolecular rearrangement.

Authors:  Wujian Ju; Sihyung Yang; John H Ansede; Chad E Stephens; Arlene S Bridges; Robert D Voyksner; Mohamed A Ismail; David W Boykin; Richard R Tidwell; James Edwin Hall; Michael Zhuo Wang
Journal:  J Pharm Sci       Date:  2013-11-01       Impact factor: 3.534

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.